Yanjie You1,2,3,4, Haijun Li5, Xin Qin6, Yinpo Zhang1, Wengang Song1, Yonggang Ran7, Fenglan Gao8. 1. Pathological Examination and Research Center, Luohe Medical College, 148 Daxue-Road, Luohe, 462002, China. 2. Department of Pharmacy, Luohe Medical College, Luohe, 462002, China. 3. Luohe Key Laboratory of Medical Bioengineering, Luohe, 462002, China. 4. Bioengineering Laboratory, Luohe Medical College, Luohe, 462002, China. 5. Department of Radiation Oncology, the Second People's Hospital of Neijiang City, Neijaing, 641000, China. 6. Medical College, Hubei University of Arts and Science, Xiangyang, 441053, China. 7. Department of Teaching and Training, Bethune Military Medical NCO Academy of PLA, Shijiazhuang, 050081, China. 8. Pathological Examination and Research Center, Luohe Medical College, 148 Daxue-Road, Luohe, 462002, China. lhyzgao@126.com.
Abstract
BACKGROUND: Cyclin-dependent kinase 10 (CDK10) has recently been identified as a tumor suppressor and, concordantly, its encoding gene has frequently been found to be inactivated in various human cancers. Here, we examined the expression status of CDK10 in a panel of primary human breast cancers and evaluated its correlation with clinicopathological parameters and clinical outcome. METHODS: Western blotting was used to assess CDK10 protein levels in 20 paired breast cancer tissues and adjacent noncancerous tissues. In addition, immunohistochemistry was performed in 128 formalin-fixed, paraffin-embedded tumor tissues. Associations of CDK10 expression with various clinicopathological parameters were evaluated and Kaplan-Meier survival analyses and Cox proportional hazards models were used to estimate its effect on patient survival. RESULTS: We found that CDK10 protein expression was markedly decreased in cancer tissues compared to adjacent noncancerous tissues. Immunohistochemistry revealed decreased CDK10 levels in 65/128 (50.8 %) of the primary breast cancer tissues tested. These decreased levels were found to be significantly associated with lymph node metastasis (P = 0.003), advanced tumor stage (P < 0.001) and unfavorable overall survival (P < 0.001). Furthermore, multivariate analyses indicated that CDK10 expression may serve as an independent prognostic factor for survival (P = 0.001). CONCLUSION: Down-regulated CDK10 expression frequently occurs in breast cancers and correlates with disease progression and poor survival. CDK10 may serve as a prognostic biomarker for breast cancer.
BACKGROUND:Cyclin-dependent kinase 10 (CDK10) has recently been identified as a tumor suppressor and, concordantly, its encoding gene has frequently been found to be inactivated in various humancancers. Here, we examined the expression status of CDK10 in a panel of primary humanbreast cancers and evaluated its correlation with clinicopathological parameters and clinical outcome. METHODS: Western blotting was used to assess CDK10 protein levels in 20 paired breast cancer tissues and adjacent noncancerous tissues. In addition, immunohistochemistry was performed in 128 formalin-fixed, paraffin-embedded tumor tissues. Associations of CDK10 expression with various clinicopathological parameters were evaluated and Kaplan-Meier survival analyses and Cox proportional hazards models were used to estimate its effect on patient survival. RESULTS: We found that CDK10 protein expression was markedly decreased in cancer tissues compared to adjacent noncancerous tissues. Immunohistochemistry revealed decreased CDK10 levels in 65/128 (50.8 %) of the primary breast cancer tissues tested. These decreased levels were found to be significantly associated with lymph node metastasis (P = 0.003), advanced tumor stage (P < 0.001) and unfavorable overall survival (P < 0.001). Furthermore, multivariate analyses indicated that CDK10 expression may serve as an independent prognostic factor for survival (P = 0.001). CONCLUSION: Down-regulated CDK10 expression frequently occurs in breast cancers and correlates with disease progression and poor survival. CDK10 may serve as a prognostic biomarker for breast cancer.
Entities:
Keywords:
Breast cancer; CDK10; Immunohistochemistry; Prognosis
Authors: Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend Journal: Nature Date: 2002-01-31 Impact factor: 49.962
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Anoek H J Verschuur-Maes; Cathy B Moelans; Peter C de Bruin; Paul J van Diest Journal: Cell Oncol (Dordr) Date: 2014-04-02 Impact factor: 6.730
Authors: S Mahale; S B Bharate; S Manda; P Joshi; P R Jenkins; R A Vishwakarma; B Chaudhuri Journal: Cell Death Dis Date: 2015-05-07 Impact factor: 8.469
Authors: Nilah M Ioannidis; Wei Wang; Nicholas A Furlotte; David A Hinds; Carlos D Bustamante; Eric Jorgenson; Maryam M Asgari; Alice S Whittemore Journal: Nat Commun Date: 2018-10-15 Impact factor: 17.694